{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:12Z","timestamp":1792202352067,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","award":["KSN1823320 and KSN2511030"],"award-info":[{"award-number":["KSN1823320 and KSN2511030"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","award":["KSN1823320 and KSN2511030"],"award-info":[{"award-number":["KSN1823320 and KSN2511030"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00352796"],"award-info":[{"award-number":["RS-2024-00352796"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00352796"],"award-info":[{"award-number":["RS-2024-00352796"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003661","name":"Korea Institute for Advancement of Technology","doi-asserted-by":"publisher","award":["RS-2024-00434342"],"award-info":[{"award-number":["RS-2024-00434342"]}],"id":[{"id":"10.13039\/501100003661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-025-03461-z","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:02:55Z","timestamp":1747458175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rebamipide (Mucosta\u00ae), a clinically approved drug, alleviates neuroinflammation and dopaminergic neurodegeneration in a Parkinson\u2019s disease model"],"prefix":"10.1186","volume":"22","author":[{"given":"Hye-Sun","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonhwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwi-Yeol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhyuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"3461_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/9781444341256.ch21","volume-title":"Neurodegeneration: the molecular pathology of dementia and movement disorders","author":"KA Jellinger","year":"2011","unstructured":"Jellinger KA. Parkinson\u2019s disease. In: Dickson DW, Weller RO, editors. Neurodegeneration: the molecular pathology of dementia and movement disorders. Oxford: Wiley-Blackwell; 2011. p. 194\u2013223."},{"key":"3461_CR2","doi-asserted-by":"crossref","unstructured":"Ureshino RP, Ram\u00edrez AL. Linking aging and animal models to neurodegeneration: the striatum, substantia nigra, and Parkinson\u2019s disease. In: Assessments, Treatments and Modeling in Aging and Neurological Disease. Elsevier; 2021. p. 539\u2013552","DOI":"10.1016\/B978-0-12-818000-6.00048-2"},{"key":"3461_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/brain\/awad322","volume":"147","author":"A Kouli","year":"2024","unstructured":"Kouli A, Spindler LR, Fryer TD, Hong YT, Malpetti M, Aigbirhio FI, et al. Neuroinflammation is linked to dementia risk in Parkinson\u2019s disease. Brain. 2024;147:923\u201335.","journal-title":"Brain"},{"key":"3461_CR4","doi-asserted-by":"publisher","first-page":"577543","DOI":"10.1016\/j.jneuroim.2021.577543","volume":"354","author":"S Huang","year":"2021","unstructured":"Huang S, Chen Z, Fan B, Chen Y, Zhou L, Jiang B, et al. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson\u2019s disease. J Neuroimmunol. 2021;354:577543.","journal-title":"J Neuroimmunol"},{"key":"3461_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","volume":"26","author":"E Lee","year":"2019","unstructured":"Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26:213\u201328.","journal-title":"Cell Death Differ"},{"key":"3461_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mds.27874","volume":"35","author":"ME Haque","year":"2020","unstructured":"Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK. Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease. Mov Disord. 2020;35:20\u201333.","journal-title":"Mov Disord"},{"key":"3461_CR7","doi-asserted-by":"crossref","unstructured":"Liu Q, Zhang M-M, Guo M-X, Zhang Q-P, Li N-Z, Cheng J, et al. Inhibition of microglial NLRP3 with MCC950 attenuates microglial morphology and NLRP3\/caspase-1\/IL-1\u03b2 signaling in stress-induced mice. J Neuroimmune Pharmacol. 2022;17:503-14. https:\/\/pubmed.ncbi.nlm.nih.gov\/34978026\/","DOI":"10.1007\/s11481-021-10037-0"},{"key":"3461_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1586\/egh.10.25","volume":"4","author":"Y Naito","year":"2010","unstructured":"Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4:261\u201370.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3461_CR9","first-page":"906","volume":"67","author":"J Liu","year":"2012","unstructured":"Liu J, Shen-Tu J, Wu L, Dou J, Xu Q, Zhou H, et al. Development of a simple LC-MS\/MS method for determination of rebamipide in human plasma and its application to a bioequivalence study. Pharmazie. 2012;67:906\u201311.","journal-title":"Pharmazie"},{"key":"3461_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1365-2036.18.s1.5.x","volume":"18","author":"R Genta","year":"2003","unstructured":"Genta R. The role of Rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003;18:8\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"3461_CR11","doi-asserted-by":"publisher","first-page":"e98390","DOI":"10.1371\/journal.pone.0098390","volume":"9","author":"R Arakaki","year":"2014","unstructured":"Arakaki R, Eguchi H, Yamada A, Kudo Y, Iwasa A, Enkhmaa T, et al. Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sj\u00f6gren\u2019s syndrome. PLoS ONE. 2014;9:e98390.","journal-title":"PLoS ONE"},{"key":"3461_CR12","doi-asserted-by":"crossref","unstructured":"Kashima T, Itakura H, Akiyama H, Kishi S. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. Clin Ophthalmol. 2014;8:1003\u201310. https:\/\/pubmed.ncbi.nlm.nih.gov\/24940041\/.","DOI":"10.2147\/OPTH.S40798"},{"key":"3461_CR13","doi-asserted-by":"crossref","unstructured":"Murakami I, Zhang R, Kubo M, Nagaoka K, Eguchi E, Ogino K. Rebamipide suppresses mite-induced asthmatic responses in NC\/Nga mice. Am J Physiol Lung Cell Mol Physiol. 2015;309:L872\u20138.","DOI":"10.1152\/ajplung.00194.2015"},{"key":"3461_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00210-017-1370-7","volume":"390","author":"AM Gendy","year":"2017","unstructured":"Gendy AM, Abdallah DM, El-Abhar HS. The potential curative effect of rebamipide in hepatic ischemia\/reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol. 2017;390:691\u2013700.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3461_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/art.38310","volume":"66","author":"SJ Moon","year":"2014","unstructured":"Moon SJ, Park JS, Woo YJ, Lim MA, Kim SM, Lee SY, et al. Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of Th17\/Treg cell differentiation and heme oxygenase 1 induction. Arthritis Rheumatol. 2014;66:874\u201385.","journal-title":"Arthritis Rheumatol"},{"key":"3461_CR16","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1111\/febs.13278","volume":"282","author":"W Li","year":"2015","unstructured":"Li W, Zhao Y, Xu X, Ma W, Gao P, Wang Y, et al. Rebamipide suppresses TNF-\u03b1 mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J. 2015;282:2317\u201326.","journal-title":"FEBS J"},{"key":"3461_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.juro.2013.11.026","volume":"191","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Yoshida M, Yamamoto T, Majima T, Takai S, Gotoh M. Intravesical application of rebamipide suppresses bladder inflammation in a rat cystitis model. J Urol. 2014;191:1147\u201352.","journal-title":"J Urol"},{"key":"3461_CR18","first-page":"24","volume":"70","author":"H Yoshida","year":"2019","unstructured":"Yoshida H, Hashimoto Y, Fukushima T, Tanji K, Matsumiya T, Seya K, et al. Effect of low-concentration amyloid-\u03b2 1\u201342 (A\u03b242) on human neuroblastoma SH-SY5Y cell viability: neuroprotective potential of combination use with carnosic acid, rebamipide, edaravone, and resveratrol. Hirosaki Igaku. 2019;70:24\u201338.","journal-title":"Hirosaki Igaku"},{"key":"3461_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neures.2017.05.005","volume":"124","author":"K Fukui","year":"2017","unstructured":"Fukui K, Yachi K, Yoshida H, Tanji K, Matsumiya T, Hayakari R, et al. Rebamipide reduces amyloid-\u03b2 1\u201342 (A\u03b242) production and ameliorates A\u03b243-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells. Neurosci Res. 2017;124:40\u201350.","journal-title":"Neurosci Res"},{"key":"3461_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12640-018-9983-2","volume":"35","author":"A Mishra","year":"2019","unstructured":"Mishra A, Krishnamurthy S. Rebamipide mitigates impairments in mitochondrial function and bioenergetics with \u03b1-synuclein pathology in 6-OHDA-induced Hemiparkinson\u2019s model in rats. Neurotox Res. 2019;35:542\u201362.","journal-title":"Neurotox Res"},{"key":"3461_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/emm.2006.40","volume":"38","author":"YS Kim","year":"2006","unstructured":"Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson\u2019s disease. Exp Mol Med. 2006;38:333\u201347.","journal-title":"Exp Mol Med"},{"key":"3461_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000320027","volume":"18","author":"DD Lofrumento","year":"2010","unstructured":"Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. NeuroImmunoModulation. 2010;18:79\u201388.","journal-title":"NeuroImmunoModulation"},{"key":"3461_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","volume":"53","author":"Y Tang","year":"2016","unstructured":"Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53:1181\u201394.","journal-title":"Mol Neurobiol"},{"key":"3461_CR24","doi-asserted-by":"publisher","first-page":"815347","DOI":"10.3389\/fnagi.2022.815347","volume":"14","author":"S Guo","year":"2022","unstructured":"Guo S, Wang H, Yin Y. Microglia polarization from M1 to M2 in neurodegenerative diseases. Front Aging Neurosci. 2022;14:815347.","journal-title":"Front Aging Neurosci"},{"key":"3461_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2020.07.010","volume":"159","author":"HS Lim","year":"2020","unstructured":"Lim HS, Moon BC, Lee J, Choi G, Park G. The insect molting hormone 20-hydroxyecdysone protects dopaminergic neurons against MPTP-induced neurotoxicity in a mouse model of Parkinson\u2019s disease. Free Radic Biol Med. 2020;159:23\u201336.","journal-title":"Free Radic Biol Med"},{"issue":"20","key":"3461_CR26","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1523\/JNEUROSCI.1069-07.2007","volume":"27","author":"GM Petzinger","year":"2007","unstructured":"Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, et al. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci. 2007;27(20):5291\u2013300.","journal-title":"J Neurosci"},{"key":"3461_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fnagi.2017.00139","volume":"9","author":"GJ Song","year":"2017","unstructured":"Song GJ, Suk K. Pharmacological modulation of functional phenotypes of microglia in neurodegenerative diseases. Front Aging Neurosci. 2017;9:139.","journal-title":"Front Aging Neurosci"},{"key":"3461_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11481-016-9720-7","volume":"12","author":"R Calvello","year":"2017","unstructured":"Calvello R, Cianciulli A, Nicolardi G, De Nuccio F, Giannotti L, Salvatore R, et al. Vitamin D treatment attenuates neuroinflammation and dopaminergic neurodegeneration in an animal model of Parkinson\u2019s disease, shifting M1 to M2 microglia responses. J Neuroimmune Pharmacol. 2017;12:327\u201339.","journal-title":"J Neuroimmune Pharmacol"},{"key":"3461_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","volume":"211","author":"J Bov\u00e9","year":"2012","unstructured":"Bov\u00e9 J, Perier C. Neurotoxin-based models of Parkinson\u2019s disease. Neuroscience. 2012;211:51\u201376.","journal-title":"Neuroscience"},{"key":"3461_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.toxlet.2016.11.002","volume":"265","author":"Q-S Zhang","year":"2017","unstructured":"Zhang Q-S, Heng Y, Yuan Y-H, Chen N-H. Pathological \u03b1-synuclein exacerbates the progression of Parkinson\u2019s disease through microglial activation. Toxicol Lett. 2017;265:30\u20137.","journal-title":"Toxicol Lett"},{"key":"3461_CR31","doi-asserted-by":"crossref","unstructured":"Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to \u03b1-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 2013;5:AN20120066.","DOI":"10.1042\/AN20120066"},{"key":"3461_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13105-022-00909-1","volume":"78","author":"Y Feng","year":"2022","unstructured":"Feng Y, Li M, Yangzhong X, Zhang X, Zu A, Hou Y, et al. Pyroptosis in inflammation-related respiratory disease. J Physiol Biochem. 2022;78:721\u201337.","journal-title":"J Physiol Biochem"},{"key":"3461_CR33","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s10495-020-01632-2","volume":"25","author":"C Wu","year":"2020","unstructured":"Wu C, Zhou L, Yuan H, Wu S. Interconnections among major forms of regulated cell death. Apoptosis. 2020;25:616\u201324.","journal-title":"Apoptosis"},{"key":"3461_CR34","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.neuron.2022.05.009","volume":"110","author":"N Panicker","year":"2022","unstructured":"Panicker N, Kam T-I, Wang H, Neifert S, Chou S-C, Kumar M, et al. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson\u2019s disease. Neuron. 2022;110:2422-37.e2429.","journal-title":"Neuron"},{"key":"3461_CR35","doi-asserted-by":"publisher","first-page":"115750","DOI":"10.1016\/j.ejmech.2023.115750","volume":"260","author":"M Duan","year":"2023","unstructured":"Duan M, Sun L, He X, Wang Z, Hou Y, Zhao Y. Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023. Eur J Med Chem. 2023;260:115750.","journal-title":"Eur J Med Chem"},{"key":"3461_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11481-019-09843-4","volume":"14","author":"S Yao","year":"2019","unstructured":"Yao S, Li L, Sun X, Hua J, Zhang K, Hao L, et al. FTY720 inhibits MPP+-induced microglial activation by affecting NLRP3 inflammasome activation. J Neuroimmune Pharmacol. 2019;14:478\u201392.","journal-title":"J Neuroimmune Pharmacol"},{"key":"3461_CR37","doi-asserted-by":"publisher","first-page":"154983","DOI":"10.1016\/j.cyto.2019.154983","volume":"127","author":"J Kim","year":"2020","unstructured":"Kim J, Ahn H, Yu S, Ahn J-H, Ko H-J, Kweon M-N, et al. I\u03baB\u03b6 controls NLRP3 inflammasome activation via upregulation of the Nlrp3 gene. Cytokine. 2020;127:154983.","journal-title":"Cytokine"},{"key":"3461_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41:301\u201316.","journal-title":"Annu Rev Immunol"},{"key":"3461_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ. Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437\u201349.","journal-title":"J Inherit Metab Dis"},{"key":"3461_CR40","doi-asserted-by":"publisher","first-page":"108471","DOI":"10.1016\/j.jmgm.2023.108471","volume":"122","author":"E Mateev","year":"2023","unstructured":"Mateev E, Kondeva-Burdina M, Georgieva M, Zlatkov A. Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer\u2019s disease: An in silico and in vitro study. J Mol Graph Model. 2023;122:108471.","journal-title":"J Mol Graph Model"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03461-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:03:00Z","timestamp":1747458180000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-025-03461-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3461"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03461-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Animal Care and Use Committee of KIOM (Approval number: IACUC-KIOM-22\u2013026, 22\u2013075, and 23\u2013060) and Macrogen, Inc. (Approval number: IACUC-MS-2023\u201301) and conducted in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}